This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Narcisi, E. M. Articles by Secor, W. E. Search for Related Content PubMed PubMed Citation Articles by Narcisi, E. M. Articles by Secor, W. E.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, May 1996, 1121-1125, Vol 40, No. 5
Copyright © 1996 by the American Society for Microbiology. All rights reserved.

In vitro effect of tinidazole and furazolidone on metronidazole- resistant Trichomonas vaginalis

EM Narcisi and WE Secor
National Center for Infectious Diseases, Centers for Disease Control and Prevention, U.S. Department of Health and Human Services, Atlanta, Georgia 30341-3717, USA.

Trichomonas vaginalis is a common sexually transmitted protozoan parasite. Although often considered simply a nuisance infection, T. vaginalis has been implicated in premature rupture of placental membranes and increases in the risk of acquiring human immunodeficiency virus. Metronidazole, a 5-nitroimidazole, is currently the drug of choice to treat T. vaginalis infection. Because some patients have severe reactions to metronidazole and others are infected with metronidazole-resistant T. vaginalis, we were prompted to investigate alternative therapies. Tinidazole, another 5-nitroimidazole used in other countries to treat T. vaginalis infections, and furazolidone, a nitrofuran presently used to treat giardiasis and infections with some anaerobic enteric bacteria, were investigated for effectiveness against 9 metronidazole-susceptible and 12 metronidazole-resistant T. vaginalis patient isolates. The in vitro aerobic and anaerobic minimum lethal concentrations (MLC) and the time for drug efficacy were determined. Tinidazole killed the metronidazole-susceptible isolates at a low MLC but was effective against only 4 of the 12 metronidazole-resistant isolates. In contrast, furazolidone was effective at a low MLC for all isolates. When tinidazole was effective, it required > 6 h to kill trichomonads. However, furazolidone killed both metronidazole- susceptible and resistant trichomonads within 2 to 3 h of exposure. These data suggest that furazolidone may be a good candidate for treating metronidazole-resistant trichomoniasis and that further investigation of this drug is warranted.

This article has been cited by other articles:

• Meneses-Marcel, A., Rivera-Borroto, O. M., Marrero-Ponce, Y., Montero, A., Machado Tugores, Y., Escario, J. A., Gomez Barrio, A., Montero Pereira, D., Nogal, J. J., Kouznetsov, V. V., Ochoa Puentes, C., Bohorquez, A. R., Grau, R., Torrens, F., Ibarra-Velarde, F., Aran, V. J. (2008). New Antitrichomonal Drug-like Chemicals Selected by Bond (Edge)-Based TOMOCOMD-CARDD Descriptors. J Biomol Screen 13: 785-794 [Abstract]  
• Ali, V., Nozaki, T. (2007). Current Therapeutics, Their Problems, and Sulfur-Containing-Amino-Acid Metabolism as a Novel Target against Infections by "Amitochondriate" Protozoan Parasites. Clin. Microbiol. Rev. 20: 164-187 [Abstract] [Full Text]  
• Cudmore, S. L., Delgaty, K. L., Hayward-McClelland, S. F., Petrin, D. P., Garber, G. E. (2004). Treatment of Infections Caused by Metronidazole-Resistant Trichomonas vaginalis. Clin. Microbiol. Rev. 17: 783-793 [Abstract] [Full Text]  
• Swygard, H, Sena, A C, Hobbs, M M, Cohen, M S (2004). Trichomoniasis: clinical manifestations, diagnosis and management. Sex. Transm. Infect. 80: 91-95 [Abstract] [Full Text]  
• Crowell, A. L., Sanders-Lewis, K. A., Secor, W. E. (2003). In Vitro Metronidazole and Tinidazole Activities against Metronidazole- Resistant Strains of Trichomonas vaginalis. Antimicrob. Agents Chemother. 47: 1407-1409 [Abstract] [Full Text]  
• Upcroft, P., Upcroft, J. A. (2001). Drug Targets and Mechanisms of Resistance in the Anaerobic Protozoa. Clin. Microbiol. Rev. 14: 150-164 [Abstract] [Full Text]  
• Snipes, L. J., Gamard, P. M., Narcisi, E. M., Beard, C. B., Lehmann, T., Secor, W. E. (2000). Molecular Epidemiology of Metronidazole Resistance in a Population of Trichomonas vaginalis Clinical Isolates. J. Clin. Microbiol. 38: 3004-3009 [Abstract] [Full Text]  
• Meri, T., Jokiranta, T. S., Suhonen, L., Meri, S. (2000). Resistance of Trichomonas vaginalis to Metronidazole: Report of the First Three Cases from Finland and Optimization of In Vitro Susceptibility Testing under Various Oxygen Concentrations. J. Clin. Microbiol. 38: 763-767 [Abstract] [Full Text]  
• Petrin, D., Delgaty, K., Bhatt, R., Garber, G. (1998). Clinical and Microbiological Aspects of Trichomonas vaginalis. Clin. Microbiol. Rev. 11: 300-317 [Abstract] [Full Text]